|
|
Article: Results of Multinational Trial Investigating Pegasys(R) and Copegus(R) in Patients with Hepatitis C and HIV Announced.
- Article from:
- PR Newswire
- Article date:
- February 7, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NUTLEY, N.J., Feb. 7 /PRNewswire/ -- Roche today announced the results of a multinational trial designed to evaluate the safety and efficacy of Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) compared with conventional interferon alfa-2a/ribavirin for the treatment of chronic hepatitis C in patients co-infected with HIV, will be presented at a conference beginning Sunday, February 8.
The results of the trial showed that a combination of Pegasys and Copegus produced significantly higher sustained virological response rates than conventional interferon and ribavirin in HCV/HIV co-infection (40% vs. 12%, P
A release with the full study results will be ...